George Warimwe
Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.Waweru G, Nyakundi R, Kutima B, Owuor S, Konyino G, Gitonga J, Lugano D, Maina A, Musyoki J, Ochola L, Omondi M, Kariuki CK, Ogongo P, Mwachari C, Shee F, Agoti C, Sande C, Uyoga S, Kagucia E, Agweyu A, Bejon P, Scott JAG, Warimwe GM, Ochola-Oyier LI, Nyagwange J
Viruses, (2025). 17:
Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional study.Anywaine Z, Wright D, Warimwe GM, Kaleebu P, Elliott A, Hansen C
BMJ Public Health, (2025). 3:e002563
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).Belij-Rammerstorfer S, Sheehan E, Li G, Bibi S, Wright D, Voysey M, Bissett C, Barman N, Camara S, Yong AA, Costa Clemens SA, Harris M, Flaxman A, Barrett J, Hussain K, Lipunga G, Shaw RH, Smith H, Cheruiyot S, Gitonga JN, Mugo D, Karanja HK, Warimwe GM, Hamaluba MM, Weckx LY, Pollard AJ, Lambe T
EBioMedicine, (2025). 118:105847
Low-Dose Yellow Fever Vaccine in Adults in Africa.Kimathi D, Juan-Giner A, Bob NS, Orindi B, Namulwana ML, Diatta A, Cheruiyot S, Fall G, Dia M, Hamaluba MM, Nyehangane D, Karanja HK, Gitonga JN, Mugo D, Omuoyo DO, Hussein M, Oloo E, Kamau N, Wafula J, Bendera J, Silvester N, Mwavita J, Joshua M, Mwendwa J, Agababyona C, Ngetsa C, Aisha N, Moki F, Buluku T, Munene M, Mwanga-Amumpaire J, Lutwama J, Kayiwa J, Kamaara E, Barrett AD, Kaleebu P, Bejon P, Sall AA, Grais RF, Warimwe GM
N Engl J Med, (2025). 392:788-797
Comparative performance of the InBios SCoV-2 Detect (TM) IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations.Kutima B, Kagucia EW, Mwai K, Kimani M, Sigilai A, Mugo D, Karanja H, Gitonga JN, Karani A, Akech D, Toroitich M, Karia B, Tuju J, Ziraba AK, Bigogo G, Ochieng C, Onyango C, Lidechi S, Munywoki PK, Uyoga S, Adetifa IMO, Oyier LIO, Bejon P, Scott JAG, Agweyu A, Warimwe GM, Nyagwange J
Wellcome Open Res, (2024). 9:349
Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.Kagucia EW, Voller S, Ziraba AK, Bigogo G, Munywoki PK, Makobu K, Nokes DJ, Nyagwange J, Orlendo C, Akech D, Sigilai A, Onyango C, Juma B, Herman-Roloff A, Munyua P, Apondi C, Lidechi S, Audi A, Ouma A, Aol G, Misore T, Nasimiyu C, Onyango D, Lo T, Kasera K, Jalang'o R, Kingwara L, Adetifa I, Etyang AO, Warimwe G, Agweyu A, Scott JAG
Gates Open Res, (2024). 8:60
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.Lugano D, Kutima B, Kimani M, Sigilai A, Gitonga J, Karani A, Akech D, Karia B, Ziraba AK, Maina A, Lambisia A, Omuoyo D, Mugo D, Lucinde R, Owuor S, Konyino G, Newman J, Bailey D, Nduati E, Githinji G, Agoti CN, Bejon P, Scott JAG, Agweyu A, Kagucia W, Warimwe GM, Sande C, Ochola-Oyier LI, Nyagwange J
BMC Infect Dis, (2024). 24:1474
Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda.Anywaine Z, Hansen C, Warimwe GM, Abu-Baker Mustapher G, Nyakarahuka L, Balinandi S, Ario AR, Lutwama JJ, Elliott A, Kaleebu P
Virol J, (2024). 21:104
Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines.Juan-Giner A, Warimwe G
Lancet Infect Dis, (2024). S1473-3099:00008-2
Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration .Kagucia EW, Voller S, Ziraba AK, Bigogo G, Munywoki PK, Makobu K, Nokes DJ, Nyagwange J, Orlendo C, Akech D, Sigilai A, Onyango C, Juma B, Herman-Roloff A, Munyua P, Apondi C, Lidechi S, Audi A, Ouma A, Aol G, Misore T, Nasimiyu C, Onyango D, Lo T, Kasera K, Jalang'o R, Kingwara L, Adetifa I, Etyang AO, Warimwe G, Agweyu A, Scott JAG
Gates Open Res, (2024). 8:
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Kimotho J, Sein Y, Sayed S, Shah R, Mwai K, Saleh M, Wanjiku P, Mwacharo J, Nyagwange J, Karanja H, Kutima B, Gitonga JN, Mugo D, Karanu A, Moranga L, Oluoch V, Shah J, Mutiso J, Mburu A, Nneka Z, Betti P, Mutinda WU, Issak Abdi A, Bejon P, Ochola-Oyier LI, Warimwe GM, Nduati EW, Ndungu FM
Wellcome Open Res, (2023). 8:350
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G
Wellcome Open Res, (2023). 8:182
Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.Downs LO, Campbell C, Abouyannis M, Otiende M, Kapulu M, Obiero CW, Hamaluba M, Ngetsa C, Andersson MI, Githinji G, Warimwe G, Baisley K, Scott JAG, Matthews PC, Etyang A
J Virus Erad, (2023). 9:100355
Symptom prevalence and secondary attack rate of SARS-CoV-2 in rural Kenyan households: A prospective cohort study.Gallagher KE, Nyiro J, Agoti CN, Maitha E, Nyagwange J, Karani A, Bottomley C, Murunga N, Githinji G, Mutunga M, Ochola-Oyier LI, Kombe I, Nyaguara A, Kagucia EW, Warimwe G, Agweyu A, Tsofa B, Bejon P, Scott JAG, Nokes DJ
Influenza Other Respir Viruses, (2023). 17:e13185
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.Kagucia EW, Ziraba AK, Nyagwange J, Kutima B, Kimani M, Akech D, Ng'oda M, Sigilai A, Mugo D, Karanja H, Gitonga J, Karani A, Toroitich M, Karia B, Otiende M, Njeri A, Aman R, Amoth P, Mwangangi M, Kasera K, Ng'ang'a W, Voller S, Ochola-Oyier LI, Bottomley C, Nyaguara A, Munywoki PK, Bigogo G, Maitha E, Uyoga S, Gallagher KE, Etyang AO, Barasa E, Mwangangi J, Bejon P, Adetifa IMO, Warimwe GM, Scott JAG, Agweyu A
Influenza Other Respir Viruses, (2023). 17:e13173
Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data.Nyandele JP, Kibondo UA, Issa F, Van Geertruyden JP, Warimwe G, Jongo S, Abdulla S, Olotu A
PLoS One, (2023). 18:e0291244
A Customizable Suite of Methods to Sequence and Annotate Cattle Antibodies.Ramirez Valdez K, Nzau B, Dorey-Robinson D, Jarman M, Nyagwange J, Schwartz JC, Freimanis G, Steyn AW, Warimwe GM, Morrison LJ, Mwangi W, Charleston B, Bonnet-Di Placido M, Hammond JA
Vaccines (Basel), (2023). 11:
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.Juan-Giner A, Namulwana ML, Kimathi D, Grantz KH, Fall G, Dia M, Bob NS, Sall AA, Nerima C, Sahani MK, Mulogo EM, Ampeire I, Hombach J, Nanjebe D, Mwanga-Amumpaire J, Cummings DAT, Bejon P, Warimwe GM, Grais RF
Lancet Infect Dis, (2023). S1473-3099:00131-7
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.Kimathi D, Juan-Giner A, Orindi B, Grantz KH, Bob NS, Cheruiyot S, Hamaluba M, Kamau N, Fall G, Dia M, Mosobo M, Moki F, Kiogora K, Chirro O, Thiong'o A, Mwendwa J, Guantai A, Karanja HK, Gitonga J, Mugo D, Ramko K, Faye O, Sanders EJ, Grais RF, Bejon P, Warimwe GM
Lancet Infect Dis, (2023). S1473-3099:00114-7
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.Jenkin D, Wright D, Folegatti PM, Platt A, Poulton I, Lawrie A, Tran N, Boyd A, Turner C, Gitonga JN, Karanja HK, Mugo D, Ewer KJ, Bowden TA, Gilbert SC, Charleston B, Kaleebu P, Hill AVS, Warimwe GM
Lancet Infect Dis, (2023). S1473-3099:00068-3
